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IgM and IgG class antibodies to cytomegalovirus 
(CMV) late antigen were studied in 58 bone marrow  
transplant (BMT) recipients and their donors using a 
sensitive enzyme-linked immunosorbent assay (ELISA) 
and with standard virological and histomorphological 
techniques. Patients who were CMV-seropositive before 
BMT had a significantly higher risk for active CMV 
infection after BMT than seronegative ones (23 of 29  
vs. 3 of 26 patients; P < l x l O “6). Transplantation of 
marrow from CMV-seropositive donors was associated 
with a higher incidence of active CMV infection after 
BMT than transplantation of marrow from seronegative  
donors (17 of 28 vs. 9 of 27 patients). Such transplan­
tations also had a significantly higher incidence of 
grades II-IV  acute graft-versus-host disease (23 of 29  
vs. 11 of 27 patients; P = 0 .0 0 7 ).
Following BMT, the evolution of the IgG class CMV 
antibody response was influenced by the serological sta­
tus of the marrow donor. First, a fall in IgG class CMV 
antibody titers during the first month after BMT was 
seen less often after transplantation of marrow from 
seropositive donors than after transplantation of mar­
row from seronegative donors. Second, recipients of 
marrow from CMV-seropositive donors who developed 
active CMV infection had an earlier IgG antibody re­
sponse than those with seronegative marrow donors. 
These results suggest that the transfer of memory B and 
T cells occurs with the graft. Failure to mount a sus­
tained IgM or IgG antibody response upon active CMV 
infection was associated with a fatal outcome.
Cytomegalovirus (CMV)9 infection occcurs frequently follow­
ing bone marrow transplantation (BMT). As a consequence of
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the profound immune deficiency tha t persists for many months 
after BMT, CMV infection is associated with a high rate of 
dissemination (1-3). In most studies, the complement fixation 
test has been used for the detection of CMV antibodies (2, 4, 
5). Recently, enzyme-linked immunosorbent assays (ELISA) 
for the detection of CMV antibodies have become available. 
They are more sensitive than complement fixation and they 
are able to detect minute changes in the antibody response to 
CMV. This characteristic is especially relevant in severely 
immunocompromised patients. Using the ELISA technique, we 
studied a series of 58 BM T recipients and their donors for 
pretransplant IgM and IgG CMV antibodies, and for the post- 
transplant evolution of the CMV antibody response. Our results 
were correlated with the clinical course posttransplantation, 
with the emphasis on complications such as acute and chronic 
graft-versus-host disease (GVHD) and nonbacterial pneumo­
nitis.
M ATERIALS AND M E T H O D S
Patients. Fifty-eight patients received bone marrow from 
their HLA-identical, MLR-nonreactive siblings. Fourteen of 
these patients with severe aplastic anemia were prepared for 
BMT with cyclophosphamide ( 5 0  mg/kg/day X 4 )  and total 
lymphoid irradiation ( 7 . 5  Gy in one session, n = l l ,  and 2 0  Gy 
in 1 0  sessions, n= 3 ) .  The 4 1  patients with acute leukemia in 
remission and the three patients with chronic granulocytic 
leukemia in chronic phase were prepared with cyclophospha­
mide ( 6 0  mg/kg/day X 2 )  and total-body irradiation ( 8  Gy in 
one session). In 2 6  of them, the lungs were shielded so as to 
receive only 6 Gy.
All patients received a median of 2.2xl08/kg nucleated bone 
marrow cells (range, 1 . 6 - 4 . 6 X 1 0 8 ) .  They were nursed in laminar 
down-flow isolators and received selective antimicrobial mod­
ulation of the gut flora (6) from day 1 5  before BM T until day 
6 0  after BMT. Transfusions of leukocyte-poor platelet concen­
trates, containing only 10-20 ml plasma, were given to maintain 
the platelet count above 10xl09/L (7). Leukocyte-poor red 
blood cells were administered to maintain the hemoglobin level 
above 5 . 0  mmol/L. Thirty-two patients received plasma infu­
sions, mainly to treat hypoproteinemia. The plasma was ob­
tained from healthy volunteer donors who had not been 
screened for CMV antibodies. The effect of the possible transfer 
of CMV antibodies was corrected for. All transfusion products 
were irradiated with 1 5  Gy prior to use.
All patients received methotrexate for the prophylaxis of 
acute GVHD. This complication was diagnosed and staged on 
the basis of clinical criteria (8 ). Therapy for acute GVHD 
consisted of corticosteroids (1-2 mg/kg/day, or 20 mg/kg/12  hr
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for 2 days). Eight patients with grades II—IV acute GVHD also 
received monoclonal antibody OKT3 (Ortho Pharmaceutical 
Co., Raritan, NJ) (9). Chronic GVHD was treated with corti­
costeroids (0 .3-1.0 mg/kg/day) and azathioprine (1-2 mg/kg/ 
day). Nonbacterial pneumonitis was defined as all forms of 
pneumonitis in which bacteria could not be identified as the 
causative agent. Thus, nonbacterial pneumonitis in this series 
comprises pneumonitis caused by CMV, Aspergillus fumigatus, 
or idiopathic interstitial pneumonitis.
Assessment of C M V  infection. Serologic studies were per­
formed once or twice prior to BMT, and at least at biweekly 
intervals after BMT for the first 100 days and at longer inter­
vals thereafter. The titers of IgM and IgG antibodies against 
CMV late antigen were determined by ELISA, as described 
elsewhere (70). Sera were tested at serial dilutions ranging from 
1:40 to 1:40960. Antibody titers ^40 were considered positive. 
Viral cultures of throat swabs, urine, and buffy coats were 
performed using standard techniques prior to BMT and at one 
to two weeks intervals during hospitalization after BMT. After 
discharge, viral cultures were performed only when clinically 
indicated. In biopsy and autopsy specimens, the characteristic 
cytopathogenic effects of CMV infection were studied. With 
respect to CMV infection, the patients were divided into four 
groups: no infection, primary infection, latent infection, and 
reactivation/reinfection (for definitions, see Table 1).
Only 2% of our blood donors have detectable IgM class CMV 
antibodies, so the IgM antibodies detected in the patients were 
considered not to have been passively transferred. The average 
titer of IgG class CMV antibodies in donor plasma is 2560. 
Consequently, IgG antibodies with titers less than 2560, in the 
period when plasma infusions were given, were not considered 
to be diagnostically significant. Based upon the serum half-life 
of IgG antibodies of about 28 days, rises in such antibody titers 
to values less than 2560 were considered diagnostically signifi­
cant only if they were sustained for at least one month after 
the last plasma infusion.
R E SU L T S
Diagnosis and incidence of C M V infection. Three patients 
with negative CMV serology and cultures died within one 
month; in two of them, autopsies provided no evidence for 
CMV infection. Since this survival was considered too short 
for proper evaluation, these patients were excluded from further 
analysis. CMV serology was consistently performed in all 55 
patients and was positive in 21 (38%); cultures were consis­
tently performed in 48 patients and were positive in 10 (21%); 
and histomorphology was studied in 30 patients and was posi­
tive in five (17%). Of the 21 patients who showed a serological 
response to CMV infection, 16 had an increase in both IgM
and IgG antibody titers and five responded only with IgG 
antibodies. We classified 26 of the 55 patients as having active 
CMV infection (47%). This definition was based on serology 
and cultures and/or histomorphology in nine; on serology only 
in 12; and on cultures and/or histomorphology only in five.
Role of pretransplant C M V antibodies in the recipient. Of the 
55 patients who were evaluable for CMV infection, 29 had IgG 
class CMV antibodies prior to BMT; four of these also had IgM 
class CMV antibodies, suggesting active infection at the time 
of BMT. Twenty-three patients (79%) had active CMV infec­
tion after BMT (Table 2). Nineteen showed significant rises in 
IgG antibody titers. In 14 of them, IgM antibodies were formed 
after BMT.
Of the 26 patients who were seronegative prior to BMT, only 
three (12%) developed active CMV infection. Two patients 
formed both IgM and IgG antibodies after BMT.
The above results suggest tha t the presence of CMV anti­
bodies in the recipient prior to BMT significantly influences 
the incidence of active CMV infection after BM T (Fisher’s 
exact test, P < l x l 0~6, 2-sided). The presence of CMV anti­
bodies prior to BMT did not influence the occurrence of the 
more severe forms (i.e., grades II—IV) of acute GVHD (Table 
3). With respect to acute GVHD, 56 patients were evaluable. 
Thirty had CMV antibodies prior to BMT, of which 19 (63%) 
developed grades II—IV acute GVHD. Fifteen (58%) of the 26 
seronegative recipients developed grades II—IV acute GVHD. 
The differences between those two groups were not significant.
Role of pretransplant C M V antibodies in the donor. Twenty-
T a b l e  2. Pre transplant CMV antibodies and active CMV infection
Pre-BMT
serology
Number of 
patients
Number of patients 
with active CMV 
infection after Percentage
Recipient Donor Total Evaluable BMT
+ + 19 17 15 88
-I- — 12 12 8 67
— + 11 11 2 18
— — 16 15 1 7
T a b l e  3. P re transplant  CMV antibodies and grades II-IV acute
GVHD
Pre-BMT
serology
Number of 
patients
Recipient Donor Total Evaluable
Number of 
patients with 
grades II-IV acute
GVHD
Percentage
+ + 19 18 14 78
- 1 -
— 12 12 5 42
—
- 1 - 11 11 9 82
— — 16 15 6 40
T a b l e  1. D e f in i t io n s  o f  ty p e s  o f  CMV in fe c tio n
Type of CMV infection
Pretransplantation Posttransplantation
Serology“ Cultures:
Histo­
morphology6
Serology" Cultures:
Histo-
morphology*IgM IgG IgM IgG
None — and — and — — and — and —
Primary — and — and — î and /or î and/or +
Latent — and + and — — and * and —
Reactivation/reinfection — and + and — î and /or î and /or +
a -  =  titer <40; -I- =  titer ^40; f =  ^4-fold rise in titer; £  = no rise in titer. 
b — =  negative; -I- =  positive.
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eight of the 55 donors whose recipients were evaluable for CMV 
infection had CMV antibodies prior to marrow donation; 27 
had only IgG antibodies, and one had both IgM and IgG 
antibodies (Table 2). Seventeen of the 28 recipients who re­
ceived marrow from those seropositive donors (61%) developed 
active CMV infection. Only nine of 27 patients with a seroneg­
ative marrow donor (33%) developed active CMV infection. 
This difference is not significant (Fisher’s exact test, p=0.08, 
2-sided).
The CMV antibody status of marrow donors significantly 
influenced the occurrence of grades II—IV acute GVHD in the 
recipients (Table 3). Twenty-three of 29 patients (79%) with 
seropositive marrow donors developed grades II—IV acute 
GVHD, whereas only 11 of 27 patients (41%) with seronegative 
marrow donors did so (Fisher's exact test, p=0.007, 2-sided).
Course of the C M V  antibody response. As can be seen from 
Table 4, patients who received marrow from seronegative do­
nors more frequently had a fall in their IgG class CMV anti­
bodies during the first five weeks after BMT (90%) than those 
with a seropositive marrow donor (47%).
The CMV antibody status of the marrow donor seemed to 
influence the timing of the IgG antibody response in the pa­
tients. Of the 26 patients with active CMV infection post BMT, 
17 had received marrow from a seropositive donor and nine 
from a seronegative one (Table 2). Five of those 17 patients did 
not show a serological response at all after BMT. Those results 
could be attributed to the early death (i.e., at day 44) of one 
patient, and to severe immune deficiency related to the occur­
rence of severe GVHD and/or the administration of monoclonal 
antibody OKT3 in four, who died at days 50, 61, 81, and 87, 
respectively. The remaining 12 patients had an IgG response 
after a median of 64 (range, 32-103) days. The IgG responses 
of the nine recipients of seronegative marrow occurred signifi­
cantly later—i.e., at a median of 92 (range, 72-162) days—than 
those of the recipients with seropositive marrow donors 
(P = 0 .01; Wilcoxon’s two-sample test).
Inspection of the occurrence times for the IgM response to 
CMV revealed only moderate differences. Ten of the 16 patients 
who formed IgM class CMV antibodies had seropositive marrow 
donors. In those patients, IgM antibodies were formed after a 
median of 73 (range, 32-177) days. Six patients had seronega­
tive marrow donors; their IgM response occurred at a median 
of 87 (range, 64-134) days.
Relationship between antibody response and the clinical out­
come of C M V infection. Sixteen of the 26 patients who devel­
oped active CMV infection formed IgM class CMV antibodies, 
and 21 showed an IgG antibody response. All of the 10 patients 
who did not form IgM class CMV antibodies died (8 from 
nonbacterial pneumonitis, 1 from septicemia, and 1 from esoph­
ageal hemorrhage). In contrast, only three of 16 patients who
T a b l e  4. IgG-class CMV antibody titers during the first five weeks
after B M T
Pre-BMT serology Number of patients Evolution of IgG class CMV antibodies
Recipient Donor Total Evaluable“ Stable or increasing Decreasing
+ -1- 19 17 9 8
+ -- 12 10 1 9
0 Four patients were excluded from analysis because they had re­
ceived plasma infusions during the first five weeks following BMT.
formed IgM antibodies died (all from nonbacterial pneumonitis; 
in two of those patients, CMV could be demonstrated as the 
causative agent) (Fisher’s exact test, P=0.0001, 2-sided).
Failure to mount a significant rise in IgG titers at all (5 
patients), or the occurrence of only a transient response (3 
patients) also was associated with an adverse outcome. All eight 
patients died; seven from nonbacterial pneumonitis. In con­
trast, only six of the 18 patients who showed a sustained IgG 
antibody response died (4 of nonbacterial pneumonitis; 2 of 
leukemic relapse) (Fisher’s exact test, P=0.004, 2-sided).
C M V  infection and acute GVHD. Acute GVHD developed in 
40 of 55 patients who were evaluable for CMV infection; grade
I in seven, grade II in 22, and grades III—IV in 11 patients. The 
median day of onset of clinical signs of acute GVHD was 26 
days (range, 11-55 days) after BMT. Active CMV infection 
developed in 18 of the 40 patients with acute GVHD: as a 
primary infection in two, and as reactivation/reinfection in 16. 
In all instances, CMV infection became manifest after the 
development of clinical GVHD. The incidence of CMV infec­
tion in the patients with grades II—IV GVHD (15 of 33 patients) 
was similar to that in the patients with grades 0-1 GVHD (11 
of 22 patients).
C M V infection and chronic GVHD. Patients who survived 
longer than 125 days were considered to be evaluable for chronic 
GVHD. This complication developed in 10 of 20 patients with­
out CMV infection, in both of two latently infected patients, 
and in nine of 19 patients with CMV reactivation/reinfection. 
In eight of the 21 patients, the chronic GVHD was extensive; 
four had CMV reactivation/reinfection, one had latent CMV 
infection, and three had no evidence of CMV infection.
Interaction between acute GVHD, C M V  infection, nonbacte­
rial pneumonitis, and mortality. An overview of the interaction 
between grades II—IV acute GVHD, active CMV infection, the 
occurrence of nonbacterial pneumonitis, and mortality is set 
out in Table 5. The occurrence of nonbacterial pneumonitis 
was significantly associated with grades II—IV GVHD (Fisher’s 
exact test, P=0.04, 2-sided), but not with CMV infection. 
Similarly, transplant-associated mortality was significantly as­
sociated with grades II—IV GVHD (Fisher’s exact test, P=0.003, 
2-sided), but not with active CMV infection.
In this patient series, nonbacterial pneumonitis was associ­
ated with a high mortality. Of the 26 patients who developed 
nonbacterial pneumonitis, 21 died of this complication (81%). 
The mortality was highest among CMV-seropositive patients
T a b l e  5. Interaction between acute GVHD, CMV infection,
nonbacterial pneumonitis, and mortality
Grades II-IV 
acute
GVHD
Active CMV 
infection
Number of patients Number of deaths6
Total With NBPn° Transplant-related
Not related 
to
transplant
+ -1- 15 9 10 1
+ -- 1 8 9 12 1
— -1- 11 3 3 1
— -- 11 2 2 3
N o t evaluable 3 3 3 0
° N B Pn =  nonbacterial pneumonitis.
h Transplant-related causes of death were: nonbacterial pneumonitis 
(n = 21), septicemia (n=3), chronic lung disease (n=2), GVHD (n=2), 
esophageal hemorrhage (n = l) ,  and venoocclusive disease (n = l) .  Causes 
of death not related to transplant were: leukemic relapse (n=4), myo­
cardial infarction (n = l) ,  and cervical dislocation (n = l) .
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(15 of 16 patients, 94%), and less in CMV-seronegative patients 
(6 of 10 patients, 60%). In eight of the 26 patients with 
nonbacterial pneumonitis, the causative agent was identified; 
it was CMV in five and Aspergillus fumigatus in three.
DISCUSSION
In 55 evaluable recipients of allogeneic marrow grafts, the 
overall incidence of active CMV infection, as determined with 
the sensitive ELISA technique for the detection of antibodies 
to CMV late antigen, was 47%. Primary infections were rela­
tively rare (12% of the recipients who were seronegative prior 
to BMT), whereas reactivations/reinfections were common 
(79% of recipients who were seropositive prior to BMT). Other 
investigators (4, 7 7), using the less sensitive complement fixa­
tion test, reported a 50-60% incidence of CMV infection, with 
equal frequencies for primary infections and reactivations/ 
reinfections. Our much higher incidence of reactivations/rein­
fections as compared with tha t of primary infections may have 
been caused by the greater sensitivity of the ELISA technique 
for detecting pretransplant antibody titers (10). Normal donor 
plasma frequently contains IgG class CMV antibodies—hence 
plasma infusions given for a prolonged period can severely 
hamper the interpretation of serological data, especially when 
sensitive techniques such as ELISA are used. T hat situation 
requires the application of strict exclusion criteria to avoid false 
positive classifications of CMV infection. The determination 
of IgM class CMV antibodies may be of value in these cases.
CMV can be transmitted by peripheral blood leukocytes (12, 
13). Consequently, the donor bone marrow and transfused 
blood products are potentially important sources of CMV. In 
our center, all platelet and red cell transfusions are depleted of 
leukocytes (7). Furthermore, none of the BM T recipients in 
this series received granulocyte transfusions. This transfusion 
policy may have prevented transmission of CMV, because only 
12% of seronegative patients developed CMV infection, which 
was fatal for those patients. Even when donors only have latent 
CMV infection, the marrow graft might serve as a vector for 
CMV infection. We found a large, but not significant difference 
in incidence of active CMV infection between patients with 
seropositive donors (61%) and those with seronegative marrow 
donors (33%).
The source of CMV in previously seropositive patients who 
develop active CMV infection is difficult to ascertain. Winston 
et al. ( 14), using restriction endonuclease analysis of viral DNA, 
showed that posttransplant infections can be due to pretrans­
plant CMV isolates. Based on the low number of primary 
infections in seronegative recipients, and on the similar expo­
sure to blood products in seropositive and seronegative recipi­
ents (data not shown), we suggest tha t reactivation of latent 
CMV, rather than reinfection with a newly acquired CMV 
strain, may be responsible for the majority of those infections.
Primary CMV infections may be clinically more important 
than reactivations or reinfections, as reported in renal trans­
plant recipients (75, 16). However, because of the small number 
of primarily infected pat ients in our study, we cannot draw firm 
conclusions on this point. Transient IgG antibody responses 
and the inability to form IgM antibodies are associated with an 
adverse outcome of CMV infection. Other groups (2, 77, 77) 
have reported an unfavorable outcome of CMV infection in 
BMT recipients with a negative complement-fixation antibody 
test. Obviously, the lack of a sustained antibody response in
these patients (of which the majority suffered from grades II- 
IV acute GVHD) indicates a state of extreme immune defi­
ciency. Recently, the administration of i.v. immunoglobulin 
preparations or CMV hyperimmune globulin has been shown 
to modify or even prevent clinical symptoms of CMV infection 
in BMT recipients (18, 19). For that reason, passive immuni­
zation of BMT recipients is now increasingly being applied.
Active CMV infection was not associated with increased 
transplant-associated mortality. In our patient series, trans­
plant-associated mortality was often preceded by grades II—IV 
acute GVHD. T hat complication was significantly associated 
with nonbacterial pneumonitis, which constituted the main 
cause of death. CMV was isolated from the lungs of only a 
minority of the patients with nonbacterial pneumonitis.
The earlier rise in the titers of IgG class CMV antibodies in 
the recipients with seropositive marrow donors, as compared 
with that of recipients with seronegative marrow donors, is 
consistent with an anamnestic response of donor-derived mem­
ory B and T  cells that may be due to the transfer of functional 
B cells or plasma cells with the bone marrow graft, as has been 
documented by Wahren et al (20). Transfer of CMV with the 
graft also may have been contributed to the earlier IgG re­
sponses in recipients of seropositive donor marrow. Finally, 
recipient-derived memory B cells may also play a role; these 
cells seem to survive chemoradiotherapy for a limited period 
( 20 ).
The analysis of CMV antibodies using a highly sensitive 
technique seems to be of clinical importance in the pretrans­
plant workup of bone marrow recipients and donors. Seropo­
sitive recipients constitute a high-risk group for active CMV 
infection. Although the occurrence of such active infections 
followed the increased immunosuppression used for treating 
acute GVHD in many patients, immunosuppression with cor­
ticosteroids per se did not cause an increased incidence of active 
CMV infections. Quinnan et al. (27) have shown tha t cytotoxic 
T lymphocytes play an important role in recovery from CMV 
infection in BMT recipients. Therefore, one should avoid overly 
aggressive immunosuppressive therapy for acute GVHD in 
these patients. Anti-T-cell monoclonal antibodies in particular, 
although beneficial in the treatment of acute GVHD, may result 
in systemic CMV infection (9).
Recently, Lonnqvist et al. (22 ) have reported an increased 
incidence of chronic GVHD in patients who previously had 
developed CMV infection. In contrast, we found an equal 
incidence of chronic GVHD among patients with and without 
CMV infection. This discrepancy might be explained by differ­
ences between the patient populations, since half of Lonnqvist’s 
patients were younger than 15 years of age. Increasing recipient 
age is also associated with chronic GVHD, so the relatively 
advanced age of our patients might have masked this effect of 
CMV infection.
Transplantation of marrow from CMV-seropositive donors 
was associated with an increased risk for grades II—IV acute 
GVHD. In mice, CMV infection greatly increases the severity 
of GVHD (23). Because acute GVHD typically develops during 
the first month after BMT and CMV infection mostly becomes 
manifest during the second, we suggest that donor-derived 
memory T  cells, reacting either in the recipient with the virus 
or with minor histocompatibility antigens tha t crossreact with 
CMV, become triggered and cause acute GVHD.
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